Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1842112
PUBLISHER: Grand View Research | PRODUCT CODE: 1842112
Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 138 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Next Generation Cancer Diagnostics Market Summary
The global next generation cancer diagnostics market size was valued at USD 16.61 billion in 2024 and is expected to reach USD 41.44 billion by 2033, growing at a CAGR of 11.15% from 2025 to 2033. The growth of the industry is anticipated to be driven by the rising incidence of oncology diseases, the need for efficient prognosis and early diagnosis of various forms of cancer, and rising initiatives by key players in the development of innovative solutions to meet the rising demand for efficient diagnostics.
Several tests, including physical examination, laboratory tests, imaging tests, and biopsy, have traditionally been performed in cancer diagnosis. Each step of the usual diagnostic procedure, with the prognosis and therapeutic decision made by oncologists, comes with a well-defined approach to avoid potential complications. This highlights the crucial importance of diagnosis throughout the entire oncology lifecycle, surpassing the therapeutic regimen's significance.
Next-generation sequencing (NGS) has become a transformative force in oncology diagnostics, enabling comprehensive genomic profiling of tumors to match patients with targeted therapies. By identifying actionable mutations and molecular alterations, NGS supports personalized medicine strategies that improve clinical outcomes. However, the impact of sequencing in routine care still requires clearer evidence stratification, as not all patients with actionable mutations ultimately receive targeted therapies. Barriers such as the timing of sequencing within the care pathway, physician interpretation, limited accessibility, and cost-effectiveness continue to restrict broader adoption.
Large-scale initiatives such as the TAPUR Study and the NCI MATCH Study aim to generate robust real-world evidence on the impact of sequencing-driven treatment selection. While CMS's National Coverage Determination expanded access by approving tests like FoundationOne CDx (F1CDx), the removal of the "coverage with evidence development" requirement has amplified calls for continuous outcome tracking, including metrics such as overall survival, progression-free survival, and response rates. Critics argue that broader panels (such as F1CDx) may add costs without always providing proportional clinical benefit, as illustrated by modest response rates in certain targeted therapy arms of NCI MATCH. This underscores the need for more evidence-based validation of sequencing-guided treatment approaches.
Beyond genomics, the field is rapidly expanding toward multi-omics integration. While DNA provides a static blueprint, complementary approaches such as RNA sequencing (transcriptomics) and proteomics (mass spectrometry) offer dynamic insights into gene expression and protein signaling pathways. Combined with metabolomics, these data layers create a holistic picture of tumor biology. Projects like TCGA have highlighted the promise of integrated-omics, though challenges remain in harmonizing these datasets into clinically actionable outputs.
At the same time, companies are accelerating the clinical deployment of such technologies. In May 2025, Illumina expanded its oncology portfolio with the launch of TruSight Oncology (TSO) Comprehensive, the first FDA-approved distributable CGP IVD kit with pan-cancer CDx claims, which is now reimbursed under Medicare and most commercial plans. The test, covering more than 500 genes, has also gained regulatory approval in Japan and is being integrated into clinical practice across community hospitals and academic centers. Illumina also deepened its partnership with Pillar Biosciences, adding the oncoReveal(R) CDx panel on the MiSeq Dx System, further democratizing access to in-house tumor profiling. Similarly, in June 2025, QIAGEN and Incyte entered a collaboration to develop a multimodal NGS companion diagnostic for myeloproliferative neoplasms, validated on the Illumina NextSeq 550Dx platform. The test will detect mutCALR mutations, supporting Incyte's innovative antibody program (INCA033989) for essential thrombocythemia and myelofibrosis. In March 2025, GenomOncology partnered with Chronetyx Laboratories to streamline clinical adoption by integrating its Pathology Workbench software with Chronetyx's FDA-cleared and CE-IVD-marked Cyx Solid Tumor 505 test, automating tertiary analysis and significantly reducing turnaround times for NGS results. Collectively, these initiatives highlight how leading players are addressing bottlenecks in reimbursement, workflow automation, and biomarker expansion to accelerate precision oncology adoption.
NGS also plays a central role in immuno-oncology diagnostics. Tumor mutational burden (TMB), PD-L1 expression, and neoantigen profiling are increasingly used as biomarkers for response to immune checkpoint inhibitors. Evidence from advanced hepatocellular carcinoma (HCC) shows that TP53 mutations correlate with improved survival, while TERT and BRD4 mutations signal poor prognosis. Exome sequencing combined with proteomics helps identify which neoantigens are presented by the major histocompatibility complex (MHC), guiding personalized immunotherapy strategies.
Emerging diagnostic modalities such as liquid biopsy and single-cell sequencing are further reshaping the market. Liquid biopsy offers a non-invasive method to detect circulating tumor DNA (ctDNA) and monitor treatment resistance in real-time. Meanwhile, single-cell sequencing reveals intratumoral heterogeneity, identifying subclones that may drive resistance or metastasis. Together, these technologies address key limitations of conventional tissue biopsies and are poised to drive faster adoption of precision oncology.
A powerful enabler of these advancements is the integration of artificial intelligence (AI) and machine learning (ML). These tools can mine vast NGS and multi-omics datasets, uncovering hidden correlations that inform predictive modeling, treatment selection, and resistance mechanisms. AI-enhanced bioinformatics pipelines are expected to improve diagnostic accuracy, reduce turnaround times, and optimize clinical decision-making, making them a critical growth driver for the next generation cancer diagnostics market.
Nevertheless, significant challenges remain. Not all mutations detected are actionable, and many fall into a gray zone with uncertain clinical utility. Ethical considerations around incidental findings, patient consent, and data privacy further complicate adoption. To maximize the potential of NGS and related technologies, standardized guidelines, stronger evidence frameworks, and multidisciplinary collaboration across oncologists, geneticists, bioinformaticians, and ethicists are essential.
Overall, the market is evolving from single-modality genomic profiling to integrated, AI-powered, multi-omics solutions. With advances such as Illumina's FDA-approved CGP assays, QIAGEN's hematology-focused companion diagnostics, and GenomOncology's workflow automation partnerships, alongside the broader adoption of liquid biopsy and immuno-oncology biomarkers, the sector is positioned for substantial growth. However, its long-term trajectory will hinge on demonstrating clear clinical utility, cost-effectiveness, and improved patient outcomes in real-world practice.
Global Next Generation Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global next generation cancer diagnostics market report based on technology, application, cancer type, function, and region:
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Next Generation Sequencing
- qPCR & Multiplexing
- LOAC & RT-PCR
- Protein Microarrays
- DNA Microarrays
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Biomarker Development
- CTC Analysis
- Proteomic Analysis
- Epigenetic Analysis
- Genetic Analysis
- Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Others
- Function Outlook (Revenue, USD Million, 2021 - 2033)
- Therapeutic Monitoring
- Companion Diagnostics
- Prognostics
- Cancer Screening
- Risk Analysis
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Product Code: 978-1-68038-738-4
Table of Contents
Chapter 1. Next Generation Cancer Diagnostics Market: Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Technology Segment
- 1.1.1.2. Application Segment
- 1.1.1.3. Cancer Type Segment
- 1.1.1.4. Function Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations
Chapter 2. Next Generation Cancer Diagnostics Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Technology and Application Snapshot
- 2.3. Cancer Type and Function Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. Next Generation Cancer Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Exponentially decreasing cost of genetic sequencing
- 3.4.2. Development of cluster chip technology and potential applications of CTC in cancer management
- 3.4.3. Rising demand for preventive medicine & companion diagnostics
- 3.4.4. Growing cancer incidence
- 3.5. Market Restraint Analysis
- 3.5.1. Requirement of expensive laboratory set-up for implementation of novel tests
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
- 3.8. Pipeline Analysis
Chapter 4. Next Generation Cancer Diagnostics Market: Technology Estimates & Trend Analysis
- 4.1. Next Generation Cancer Diagnostics Market: Technology Movement Analysis
- 4.2. Next Generation Sequencing
- 4.2.1. Next Generation Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 4.3. qPCR & Multiplexing
- 4.3.1. qPCR & Multiplexing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 4.4. LOAC & RT-PCR
- 4.4.1. LOAC & RT-PCR Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 4.5. Protein Microarrays
- 4.5.1. Protein Microarrays Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 4.6. DNA Microarrays
- 4.6.1. DNA Microarrays Market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Next Generation Cancer Diagnostics Market: Application Estimates & Trend Analysis
- 5.1. Next Generation Cancer Diagnostics Market: Application Movement Analysis
- 5.2. Biomarker Development
- 5.2.1. Biomarker Development Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. CTC Analysis
- 5.3.1. CTC Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Proteomic Analysis
- 5.4.1. Proteomic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Epigenetic Analysis
- 5.5.1. Epigenetic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Genetic Analysis
- 5.6.1. Genetic Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Next Generation Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
- 6.1. Next Generation Cancer Diagnostics Market: Cancer Type Movement Analysis
- 6.2. Lung Cancer
- 6.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Breast Cancer
- 6.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Colorectal Cancer
- 6.4.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Cervical Cancer
- 6.5.1. Cervical Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Next Generation Cancer Diagnostics Market: Function Estimates & Trend Analysis
- 7.1. Next Generation Cancer Diagnostics Market: Cancer Type Movement Analysis
- 7.2. Therapeutic Monitoring
- 7.2.1. Therapeutic Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3. Companion Diagnostics
- 7.3.1. Companion Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Prognostics
- 7.4.1. Prognostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Cancer Screening
- 7.5.1. Cancer Screening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Risk Analysis
- 7.6.1. Risk Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Next Generation Cancer Diagnostics Market: Regional Business Analysis
- 8.1. Regional Market Snapshot
- 8.2. North America
- 8.2.1. North America Next Generation Cancer Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.2.2.2. Key Country Dynamics
- 8.2.2.3. Regulatory Framework
- 8.2.2.4. Reimbursement Scenario
- 8.2.2.5. Competitive Scenario
- 8.2.3. CANADA
- 8.2.3.1. Canada Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.2.3.2. Key Country Dynamics
- 8.2.3.3. Regulatory Framework
- 8.2.3.4. Reimbursement Scenario
- 8.2.3.5. Competitive Scenario
- 8.2.4. MEXICO
- 8.2.4.1. Mexico Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.2.4.2. Key Country Dynamics
- 8.2.4.3. Regulatory Framework
- 8.2.4.4. Reimbursement Scenario
- 8.2.4.5. Competitive Scenario
- 8.3. Europe
- 8.3.1. Europe Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.2. UK
- 8.3.2.1. UK Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.2.2. Key Country Dynamics
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. Reimbursement Scenario
- 8.3.2.5. Competitive Scenario
- 8.3.3. GERMANY
- 8.3.3.1. Germany Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.3.2. Key Country Dynamics
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Reimbursement Scenario
- 8.3.3.5. Competitive Scenario
- 8.3.4. SPAIN
- 8.3.4.1. Spain Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.4.2. Key Country Dynamics
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. Reimbursement Scenario
- 8.3.4.5. Competitive Scenario
- 8.3.5. FRANCE
- 8.3.5.1. France Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.5.2. Key Country Dynamics
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. Reimbursement Scenario
- 8.3.5.5. Competitive Scenario
- 8.3.6. ITALY
- 8.3.6.1. Italy Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.6.2. Key Country Dynamics
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. Reimbursement Scenario
- 8.3.6.5. Competitive Scenario
- 8.3.7. DENMARK
- 8.3.7.1. Denmark Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.7.2. Key Country Dynamics
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Reimbursement Scenario
- 8.3.7.5. Competitive Scenario
- 8.3.8. SWEDEN
- 8.3.8.1. Sweden Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.8.2. Key Country Dynamics
- 8.3.8.3. Regulatory Framework
- 8.3.8.4. Reimbursement Scenario
- 8.3.8.5. Competitive Scenario
- 8.3.9. NORWAY
- 8.3.9.1. Norway Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.3.9.2. Key Country Dynamics
- 8.3.9.3. Regulatory Framework
- 8.3.9.4. Reimbursement Scenario
- 8.3.9.5. Competitive Scenario
- 8.4. Asia Pacific
- 8.4.1. Asia-Pacific Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.2. JAPAN
- 8.4.2.1. Japan Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.2.2. Key Country Dynamics
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Scenario
- 8.4.2.5. Competitive Scenario
- 8.4.3. CHINA
- 8.4.3.1. China Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.3.2. Key Country Dynamics
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Scenario
- 8.4.3.5. Competitive Scenario
- 8.4.4. INDIA
- 8.4.4.1. India Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.4.2. Key Country Dynamics
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Scenario
- 8.4.4.5. Competitive Scenario
- 8.4.5. SOUTH KOREA
- 8.4.5.1. South Korea Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.5.2. Key Country Dynamics
- 8.4.5.3. Regulatory Framework
- 8.4.5.4. Reimbursement Scenario
- 8.4.5.5. Competitive Scenario
- 8.4.6. THAILAND
- 8.4.6.1. Thailand Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.6.2. Key Country Dynamics
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Reimbursement Scenario
- 8.4.6.5. Competitive Scenario
- 8.4.7. AUSTRALIA
- 8.4.7.1. Australia Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.4.7.2. Key Country Dynamics
- 8.4.7.3. Regulatory Framework
- 8.4.7.4. Reimbursement Scenario
- 8.4.7.5. Competitive Scenario
- 8.5. Latin America
- 8.5.1. Latin America Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.5.2. BRAZIL
- 8.5.2.1. Brazil Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.5.2.2. Key Country Dynamics
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Scenario
- 8.5.2.5. Competitive Scenario
- 8.5.3. ARGENTINA
- 8.5.3.1. Argentina Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.5.3.2. Key Country Dynamics
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Scenario
- 8.5.3.5. Competitive Scenario
- 8.6. MEA
- 8.6.1. MEA Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.6.2. SOUTH AFRICA
- 8.6.2.1. South Africa Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.6.2.2. Key Country Dynamics
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Scenario
- 8.6.2.5. Competitive Scenario
- 8.6.3. SAUDI ARABIA
- 8.6.3.1. Saudi Arabia Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.6.3.2. Key Country Dynamics
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Scenario
- 8.6.3.5. Competitive Scenario
- 8.6.4. UAE
- 8.6.4.1. UAE Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.6.4.2. Key Country Dynamics
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Scenario
- 8.6.4.5. Competitive Scenario
- 8.6.5. KUWAIT
- 8.6.5.1. Kuwait Next Generation Cancer Diagnostics Market, 2021 - 2033 (USD Million)
- 8.6.5.2. Key Country Dynamics
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Scenario
- 8.6.5.5. Competitive Scenario
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.2.1. NEW PRODUCT LAUNCH
- 9.2.2. PARTNERSHIPS
- 9.2.3. ACQUISITION
- 9.2.4. COLLABORATION
- 9.2.5. FUNDING
- 9.3. Key Company Market Share Analysis, 2024
- 9.4. Company Heat Map Analysis
- 9.5. Company Profiles
- 9.5.1. JANSSEN PHARMACEUTICALS, INC.
- 9.5.1.1. Company Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. NOVARTIS AG
- 9.5.2.1. Company Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. F. HOFFMANN-LA ROCHE LTD
- 9.5.3.1. Company Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. KONINKLIJKE PHILIPS N.V.
- 9.5.4.1. Company Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. ABBOTT
- 9.5.5.1. Company Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.6. GE HEALTHCARE
- 9.5.6.1. Company Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. THERMO FISHER SCIENTIFIC, INC.
- 9.5.7.1. Company Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. AGILENT TECHNOLOGIES, INC. (DAKO)
- 9.5.8.1. Company Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. ILLUMINA, INC.
- 9.5.9.1. Company Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. QIAGEN
- 9.5.10.1. Company Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.11. CEPHEID
- 9.5.11.1. Company Overview
- 9.5.11.2. Financial Performance
- 9.5.11.3. Product Benchmarking
- 9.5.11.4. Strategic Initiatives
- 9.5.12. OPKO HEALTH, INC.
- 9.5.12.1. Company Overview
- 9.5.12.2. Financial Performance
- 9.5.12.3. Product Benchmarking
- 9.5.12.4. Strategic Initiatives
- 9.5.13. HOLOGIC, INC (GEN-PROBE)
- 9.5.13.1. Company Overview
- 9.5.13.2. Financial Performance
- 9.5.13.3. Product Benchmarking
- 9.5.13.4. Strategic Initiatives
- 9.5.14. PERKINELMER INC.
- 9.5.14.1. Company Overview
- 9.5.14.2. Financial Performance
- 9.5.14.3. Product Benchmarking
- 9.5.14.4. Strategic Initiatives
- 9.5.15. SYSMEX
- 9.5.15.1. Company Overview
- 9.5.15.2. Financial Performance
- 9.5.15.3. Product Benchmarking
- 9.5.15.4. Strategic Initiatives
- 9.5.16. MYRIAD GENETICS, INC.
- 9.5.16.1. Company Overview
- 9.5.16.2. Financial Performance
- 9.5.16.3. Product Benchmarking
- 9.5.16.4. Strategic Initiatives
- 9.5.17. ALMAC GROUP
- 9.5.17.1. Company Overview
- 9.5.17.2. Financial Performance
- 9.5.17.3. Product Benchmarking
- 9.5.17.4. Strategic Initiatives
- 9.5.18. EXOSOME DIAGNOSTICS, INC.
- 9.5.18.1. Company Overview
- 9.5.18.2. Financial Performance
- 9.5.18.3. Product Benchmarking
- 9.5.18.4. Strategic Initiatives
- 9.5.19. GENOMIC HEALTH, INC.
- 9.5.19.1. Company Overview
- 9.5.19.2. Financial Performance
- 9.5.19.3. Product Benchmarking
- 9.5.19.4. Strategic Initiatives
- 9.5.1. JANSSEN PHARMACEUTICALS, INC.
Product Code: 978-1-68038-738-4
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviation
- Table 3 North America next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
- Table 4 North America next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 5 North America next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 6 North America next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 7 North America next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 8 U.S next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 9 U.S next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 10 U.S next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 11 U.S. next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 12 Canada next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 13 Canada next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 14 Canada next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 15 Canada next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 16 Europe next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
- Table 17 Europe next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 18 Europe next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 19 Europe next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 20 Europe next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 21 UK next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 22 UK next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 23 UK next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 24 UK next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 25 Germany next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 26 Germany next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 27 Germany next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 28 Germany next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 29 France next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 30 France next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 31 France next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 32 France next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 33 Italy next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 34 Italy next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 35 Italy next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 36 Italy next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 37 Spain next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 38 Spain next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 39 Spain next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 40 Spain next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 41 Denmark next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 42 Denmark next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 43 Denmark next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 44 Denmark next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 45 Sweden next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 46 Sweden next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 47 Sweden next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 48 Sweden next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 49 Norway next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 50 Norway next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 51 Norway next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 52 Norway next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 53 Asia Pacific next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
- Table 54 Asia Pacific next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 55 Asia Pacific next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 56 Asia Pacific next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 57 Asia Pacific next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 58 China next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 59 China next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 60 China next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 61 China next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 62 Japan next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 63 Japan next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 64 Japan next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 65 Japan next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 66 India next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 67 India next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 68 India next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 69 India next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 70 South Korea next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 71 South Korea next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 72 South Korea next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 73 South Korea next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 74 Australia next generation cancer diagnostics market, by technology 2021 - 2033 (USD Million)
- Table 75 Australia next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 76 Australia next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 77 Australia next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 78 Thailand next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 79 Thailand next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 80 Thailand next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 81 Thailand next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 82 Latin America next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
- Table 83 Latin America next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 84 Latin America next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 85 Latin America next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 86 Latin America next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 87 Brazil next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 88 Brazil next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 89 Brazil next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 90 Brazil next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 91 Mexico next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 92 Mexico next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 93 Mexico next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 94 Mexico next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 95 Argentina next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 96 Argentina next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 97 Argentina next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 98 Argentina next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 99 Middle East & Africa next generation cancer diagnostics market, by country, 2021 - 2033 (USD Million)
- Table 100 Middle East & Africa next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 101 Middle East & Africa next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 102 Middle East & Africa next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 103 Middle East & Africa next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 104 South Africa next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 105 South Africa next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 106 South Africa next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 107 South Africa next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 108 Saudi Arabia next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 109 Saudi Arabia next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 110 Saudi Arabia next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 111 Saudi Arabia next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 112 UAE next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 113 UAE next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 114 UAE next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 115 UAE next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
- Table 116 Kuwait next generation cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
- Table 117 Kuwait next generation cancer diagnostics market, by application, 2021 - 2033 (USD Million)
- Table 118 Kuwait next generation cancer diagnostics market, by cancer type, 2021 - 2033 (USD Million)
- Table 119 Kuwait next generation cancer diagnostics market, by function, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Market summary
- Fig. 4 Market segmentation & scope
- Fig. 5 Market size and growth prospects
- Fig. 6 Global next generation cancer diagnostics market - Key market driver analysis
- Fig. 7 Global next generation cancer diagnostics market - Key market restraint analysis
- Fig. 8 Penetration & growth prospect mapping
- Fig. 9 Global next generation cancer diagnostics market - Porter's analysis
- Fig. 10 Global next generation cancer diagnostics market - PESTEL analysis
- Fig. 11 Global next generation cancer diagnostics market technology outlook key takeaways
- Fig. 12 Global next generation cancer diagnostics market: Technology movement analysis
- Fig. 13 Next generation sequencing market estimates, 2021 - 2033 (USD Million)
- Fig. 14 qPCR & multiplexing market estimates, 2021 - 2033 (USD Million)
- Fig. 15 LOAC & RT-PCR market estimates, 2021 - 2033 (USD Million)
- Fig. 16 Protein microarrays market estimates, 2021 - 2033 (USD Million)
- Fig. 17 DNA microarrays market estimates, 2021 - 2033 (USD Million)
- Fig. 18 Global next generation cancer diagnostics market application outlook key takeaways
- Fig. 19 Global next generation cancer diagnostics market: application movement analysis
- Fig. 20 Biomarker development market estimates, 2021 - 2033 (USD Million)
- Fig. 21 CTC analysis market estimates, 2021 - 2033 (USD Million)
- Fig. 22 Proteomic analysis market estimates, 2021 - 2033 (USD Million)
- Fig. 23 Epigenetic analysis market estimates, 2021 - 2033 (USD Million)
- Fig. 24 Global next generation cancer diagnostics market cancer type outlook key takeaways
- Fig. 25 Global next generation cancer diagnostics market: Cancer type movement analysis
- Fig. 26 Lung cancer market estimates, 2021 - 2033 (USD Million)
- Fig. 27 Breast cancer market estimates, 2021 - 2033 (USD Million)
- Fig. 28 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
- Fig. 29 Cervical cancer market estimates, 2021 - 2033 (USD Million)
- Fig. 30 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 31 Global next generation cancer diagnostics market function outlook key takeaways
- Fig. 32 Global next generation cancer diagnostics market: Function movement analysis
- Fig. 33 Therapeutic monitoring market estimates, 2021 - 2033 (USD Million)
- Fig. 34 Companion diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 35 Prognostics market estimates, 2021 - 2033 (USD Million)
- Fig. 36 Cancer screening market estimates, 2021 - 2033 (USD Million)
- Fig. 37 Risk analysis market estimates, 2021 - 2033 (USD Million)
- Fig. 38 Regional marketplace: Key takeaways
- Fig. 39 Global next generation cancer diagnostics market: Regional movement analysis
- Fig. 40 North America next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 41 U.S. next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 42 Canada next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 43 Europe next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 44 UK next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 45 Germany next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 46 France next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 47 Spain next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 48 Italy next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 49 Denmark next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 50 Sweden next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 51 Norway next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 52 Asia Pacific next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 53 Japan next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 54 China next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 55 India next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 56 South Korea next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 57 Australia next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 58 Thailand next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 59 Latin America next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 60 Brazil next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 61 Mexico next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 62 Argentina next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 63 MEA next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 64 South Africa next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 65 Saudi Arabia next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 66 UAE next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 67 Kuwait next generation cancer diagnostics market, 2021 - 2033 (USD Million)
- Fig. 68 Strategy framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.